【摘要】 目的 探討肺耐藥蛋白(lung resistance protein, LRP)在胰腺癌細(xì)胞株中的表達(dá)及意義。方法 采用反轉(zhuǎn)錄多聚酶鏈反應(yīng)(RT-PCR)和免疫細(xì)胞化學(xué)方法檢測8株胰腺癌細(xì)胞株（SW1990、PCT-2、PCT-3、PCT-4、Aspc-1、Capan-1、Mia-PaCa-2及Panc-1）中LRP在基因水平和蛋白水平的表達(dá)。結(jié)果 RT-PCR結(jié)果顯示，在胰腺癌細(xì)胞株P(guān)CT-2中未檢測到LRP mRNA的表達(dá)，在PCT-4、Aspc-1和Panc-1中，LRP mRNA表達(dá)條帶較強(qiáng)； 在SW1990、PCT-3、Capan-1和Mia-PaCa-2中LRP mRNA表達(dá)條帶較弱； 半定量平均表達(dá)水平為0.56±0.33。免疫細(xì)胞化學(xué)結(jié)果證實(shí),在PCT-2細(xì)胞中無LRP蛋白表達(dá)，PCT-3細(xì)胞中LRP蛋白弱表達(dá)，SW1990、Aspc-1和Capan-1細(xì)胞中LRP蛋白中度表達(dá)，而在PCT-4、Mia-PaCa-2和Panc-1細(xì)胞中可見LRP蛋白的過度表達(dá)。 結(jié)論 在胰腺癌細(xì)胞中存在LRP的先天性表達(dá)，LRP過表達(dá)可能是介導(dǎo)胰腺癌細(xì)胞先天性耐藥的重要機(jī)理之一。
引用本文： 郭俊超,閆長青,廖泉,趙玉沛. 肺耐藥蛋白在胰腺癌細(xì)胞中的表達(dá)及意義. 中國普外基礎(chǔ)與臨床雜志, 2006, 13(5): 502-505. doi: 復(fù)制
| 1. | 郭俊超. 多藥耐藥基因與胰腺癌化療 [J]. 胰腺病學(xué), 2002; 2(4)∶247. |
| 2. | 張立陽, 趙玉沛, 廖 泉, 等. MDR1在胰腺癌細(xì)胞株中的表達(dá)及其意義 [J]. 中華實(shí)驗(yàn)外科雜志， 2003; 20(5)∶475. |
| 3. | 張立陽, 趙玉沛, 吳元德， 等. 胰腺癌阿霉素耐藥細(xì)胞株SW1990/ADM的建立及其耐藥機(jī)理研究 [J]. 中國普外基礎(chǔ)與臨床雜志， 2005; 12(1)∶46. |
| 4. | 潘 博, 郭俊超, 廖 泉, 等. 吉西他濱與胰腺癌化療耐藥 [J]. 中國普外基礎(chǔ)與臨床雜志, 2005; 12(5)∶503. |
| 5. | 郭俊超, 趙玉沛, 廖 泉, 等. 胰腺癌耐藥細(xì)胞株SW1990/FU的建立、 鑒定及生物學(xué)特性 [J]. 中國醫(yī)學(xué)科學(xué)院學(xué)報(bào), 2005; 27(5)∶592. |
| 6. | Berger W, Elbling L, Micksche M. Expression of the major va-ult protein LRP in human non-small-cell lung cancer cells: activation by short-term exposure to antineoplastic drugs [J].Int J Cancer, 2000; 88(2)∶293. |
| 7. | Fan K, Fan D, Cheng L, et al. Expression of multidrug resistance-related markers in gastric cancer [J]. Anticancer Res, 2000; 20(6C)∶4809. |
| 8. | Raidl M, Berger W, Schulte-Hermann R, et al. Expression of the lung resistance-related protein in human and rat hepatocarcinogenesis [J]. Am J Physiol Gastrointest Liver Physiol, 2002; 283(5)∶G1117. |
| 9. | Schneider J, Gonzalez-Roces S, Pollan M, et al. Expression of LRP and MDR1 in locally advanced breast cancer predicts axillary node invasion at the time of rescue mastectomy after induction chemotherapy [J]. Breast Cancer Res, 2001; 3(3)∶183. |
| 10. | Scheper RJ, Broxterman HJ, Scheffer GL, et al. Overexpression of a M(r) 110,000 vesicular protein in non-P-glycoprotein-mediated multidrug resistance [J]. Cancer Res, 1993; 53(7)∶1475. |
| 11. | Izquierdo MA, Scheffer GL, Flens MJ, et al. Major vault protein LRP-related multidrug resistance [J]. Eur J Cancer, 1996; 32A(6)∶979. |
| 12. | Mandoky L, Geczi L, Doleschall Z, et al. Expression and prognostic value of the lung resistance-related protein(LRP) in germ cell testicular tumors [J]. Anticancer Res, 2004; 24(2C)∶1097. |
| 13. | Olson DP, Taylor BJ, La M, et al. The prognostic significance of P-glycoprotein, multidrug resistance-related protein 1 and lung resistance protein in pediatric acute lymphoblastic leukemia: a retrospective study of 295 newly diagnosed patients by the Children’s Oncology Group [J]. Leuk Lymphoma, 2005; 46(5)∶681. |
| 14. | Izquierdo MA, Scheffer GL, Flens MJ, et al. Broad distribution of the multidrug resistance-related vault lung resistance protein in normal human tissues and tumors [J]. Am J Pathol, 1996; 148(3)∶877. |
| 15. | Liu B, Staren ED, Iwamura T, et al. Mechanisms of taxotere-related drug resistance in pancreatic carcinoma [J]. J Surg Res, 2001; 99(2)∶179. |
| 16. | Qadir M, O’Loughlin KL, Fricke SM, et al. Cyclosporin A is a broad-spectrum multidrug resistance modulator [J]. Clin Cancer Res, 2005; 11(6)∶2320. |
- 1. 郭俊超. 多藥耐藥基因與胰腺癌化療 [J]. 胰腺病學(xué), 2002; 2(4)∶247.
- 2. 張立陽, 趙玉沛, 廖 泉, 等. MDR1在胰腺癌細(xì)胞株中的表達(dá)及其意義 [J]. 中華實(shí)驗(yàn)外科雜志， 2003; 20(5)∶475.
- 3. 張立陽, 趙玉沛, 吳元德， 等. 胰腺癌阿霉素耐藥細(xì)胞株SW1990/ADM的建立及其耐藥機(jī)理研究 [J]. 中國普外基礎(chǔ)與臨床雜志， 2005; 12(1)∶46.
- 4. 潘 博, 郭俊超, 廖 泉, 等. 吉西他濱與胰腺癌化療耐藥 [J]. 中國普外基礎(chǔ)與臨床雜志, 2005; 12(5)∶503.
- 5. 郭俊超, 趙玉沛, 廖 泉, 等. 胰腺癌耐藥細(xì)胞株SW1990/FU的建立、 鑒定及生物學(xué)特性 [J]. 中國醫(yī)學(xué)科學(xué)院學(xué)報(bào), 2005; 27(5)∶592.
- 6. Berger W, Elbling L, Micksche M. Expression of the major va-ult protein LRP in human non-small-cell lung cancer cells: activation by short-term exposure to antineoplastic drugs [J].Int J Cancer, 2000; 88(2)∶293.
- 7. Fan K, Fan D, Cheng L, et al. Expression of multidrug resistance-related markers in gastric cancer [J]. Anticancer Res, 2000; 20(6C)∶4809.
- 8. Raidl M, Berger W, Schulte-Hermann R, et al. Expression of the lung resistance-related protein in human and rat hepatocarcinogenesis [J]. Am J Physiol Gastrointest Liver Physiol, 2002; 283(5)∶G1117.
- 9. Schneider J, Gonzalez-Roces S, Pollan M, et al. Expression of LRP and MDR1 in locally advanced breast cancer predicts axillary node invasion at the time of rescue mastectomy after induction chemotherapy [J]. Breast Cancer Res, 2001; 3(3)∶183.
- 10. Scheper RJ, Broxterman HJ, Scheffer GL, et al. Overexpression of a M(r) 110,000 vesicular protein in non-P-glycoprotein-mediated multidrug resistance [J]. Cancer Res, 1993; 53(7)∶1475.
- 11. Izquierdo MA, Scheffer GL, Flens MJ, et al. Major vault protein LRP-related multidrug resistance [J]. Eur J Cancer, 1996; 32A(6)∶979.
- 12. Mandoky L, Geczi L, Doleschall Z, et al. Expression and prognostic value of the lung resistance-related protein(LRP) in germ cell testicular tumors [J]. Anticancer Res, 2004; 24(2C)∶1097.
- 13. Olson DP, Taylor BJ, La M, et al. The prognostic significance of P-glycoprotein, multidrug resistance-related protein 1 and lung resistance protein in pediatric acute lymphoblastic leukemia: a retrospective study of 295 newly diagnosed patients by the Children’s Oncology Group [J]. Leuk Lymphoma, 2005; 46(5)∶681.
- 14. Izquierdo MA, Scheffer GL, Flens MJ, et al. Broad distribution of the multidrug resistance-related vault lung resistance protein in normal human tissues and tumors [J]. Am J Pathol, 1996; 148(3)∶877.
- 15. Liu B, Staren ED, Iwamura T, et al. Mechanisms of taxotere-related drug resistance in pancreatic carcinoma [J]. J Surg Res, 2001; 99(2)∶179.
- 16. Qadir M, O’Loughlin KL, Fricke SM, et al. Cyclosporin A is a broad-spectrum multidrug resistance modulator [J]. Clin Cancer Res, 2005; 11(6)∶2320.